185 related articles for article (PubMed ID: 30259091)
1. Clinical translation of [
Dubash SR; Merchant S; Heinzmann K; Mauri F; Lavdas I; Inglese M; Kozlowski K; Rama N; Masrour N; Steel JF; Thornton A; Lim AK; Lewanski C; Cleator S; Coombes RC; Kenny L; Aboagye EO
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2285-2299. PubMed ID: 30259091
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography.
Witney TH; Fortt R; Aboagye EO
PLoS One; 2014; 9(3):e91694. PubMed ID: 24618809
[TBL] [Abstract][Full Text] [Related]
3. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging.
Nguyen QD; Lavdas I; Gubbins J; Smith G; Fortt R; Carroll LS; Graham MA; Aboagye EO
Clin Cancer Res; 2013 Jul; 19(14):3914-24. PubMed ID: 23729364
[TBL] [Abstract][Full Text] [Related]
4. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry.
Challapalli A; Kenny LM; Hallett WA; Kozlowski K; Tomasi G; Gudi M; Al-Nahhas A; Coombes RC; Aboagye EO
J Nucl Med; 2013 Sep; 54(9):1551-6. PubMed ID: 23949910
[TBL] [Abstract][Full Text] [Related]
5. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
[TBL] [Abstract][Full Text] [Related]
6. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11.
Nguyen QD; Challapalli A; Smith G; Fortt R; Aboagye EO
Eur J Cancer; 2012 Mar; 48(4):432-40. PubMed ID: 22226480
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.
Nguyen QD; Smith G; Glaser M; Perumal M; Arstad E; Aboagye EO
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16375-80. PubMed ID: 19805307
[TBL] [Abstract][Full Text] [Related]
8. Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer.
Chen DL; Engle JT; Griffin EA; Miller JP; Chu W; Zhou D; Mach RH
Mol Imaging Biol; 2015 Jun; 17(3):384-93. PubMed ID: 25344147
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.
Vassileva V; Stribbling SM; Barnes C; Carroll L; Braga M; Abrahams J; Heinzmann K; Haegeman C; MacFarlane M; Simpson KL; Dive C; Honeychurch J; Illidge TM; Aboagye EO
EJNMMI Res; 2019 Feb; 9(1):18. PubMed ID: 30783791
[TBL] [Abstract][Full Text] [Related]
10. Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity.
Fortt R; Smith G; Awais RO; Luthra SK; Aboagye EO
Nucl Med Biol; 2012 Oct; 39(7):1000-5. PubMed ID: 22575271
[TBL] [Abstract][Full Text] [Related]
11. Development of [
García-Argüello SF; Lopez-Lorenzo B; Cornelissen B; Smith G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781531
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.
Veronese M; Rizzo G; Aboagye EO; Bertoldo A
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1781-92. PubMed ID: 24705620
[TBL] [Abstract][Full Text] [Related]
14. Caspase-Based PET for Evaluating Pro-Apoptotic Treatments in a Tuberculosis Mouse Model.
Ordonez AA; Abhishek S; Singh AK; Klunk MH; Azad BB; Aboagye EO; Carroll L; Jain SK
Mol Imaging Biol; 2020 Dec; 22(6):1489-1494. PubMed ID: 32232626
[TBL] [Abstract][Full Text] [Related]
15. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I.
Wang F; Fang W; Zhang MR; Zhao M; Liu B; Wang Z; Hua Z; Yang M; Kumata K; Hatori A; Yamasaki T; Yanamoto K; Suzuki K
J Nucl Med; 2011 Apr; 52(4):592-9. PubMed ID: 21421722
[TBL] [Abstract][Full Text] [Related]
17. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy.
Palner M; Shen B; Jeon J; Lin J; Chin FT; Rao J
J Nucl Med; 2015 Sep; 56(9):1415-21. PubMed ID: 26045308
[TBL] [Abstract][Full Text] [Related]
19. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy.
Odonkor CA; Achilefu S
Cancer Invest; 2009 May; 27(4):417-29. PubMed ID: 19241192
[TBL] [Abstract][Full Text] [Related]
20. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
